In 586 people with early-stage Parkinson's disease on stable symptomatic medication, intravenous prasinezumab did not significantly delay confirmed motor progression versus placebo (HR 0·84, 95% CI 0·69–1·01; p=0·066); serious adverse events 12% in both groups.
RCTn = 586
Nikolcheva et al. Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study